Opti-ox enables the production of unlimited batches of any cell in the human body. Credit: bit.bio.

UK-based bit.bio has raised $103m through a Series B funding round to accelerate the clinical development of cell therapies.

The funding round saw participation from new and existing institutional and strategic investors, including National Resilience, Puhua Capital, Charles River Laboratories, Foresite Capital, Arch Ventures, Metaplanet and Tencent.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The funds will be used to speed up the clinical development of the cell coding technology opti-ox, which is a gene engineering approach.

Combining synthetic and stem cell biology, the technology enables the production of any cell in the human body in unlimited batches by directly reprogramming stem cells.

The funds will also be used to support the growth of bit.bio’s ioCells product portfolio, where opti-oxTM is leveraged to produce unique human cell products.

bit.bio CEO and founder Mark Kotter said: “I’m thrilled that bit.bio is supported by world-class investors and strategic partners.

“The capital will enable us to accelerate our clinical and commercial scale-up and to deliver cell therapies for every patient, everywhere.”

The ioCells access will allow bit.bio’s customers and partners to carry out research and develop drugs using physiologically-relevant models of human cells.

According to the company, human cells are used to fill the translation gap in drug development to increase the chances of clinical success and also tap the potential to develop new generations of drugs.

bit.bio has already introduced two products, glutamatergic neurons and skeletal myocytes, for research and drug discovery.